A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital

Anupama M; Sharath Kumar JV; Shetty GG

doi:10.5455/njppp.2023.13.09472202202102022

2026, Vol: 16, Issue: 1

16 / 1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 12 Oct 2022

Natl J Physiol Pharm Pharmacol. 2022; 12(11): 1848-1853

doi: 10.5455/njppp.2023.13.09472202202102022

A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital

Anupama M, Sharath Kumar Jv, Shetty Gg.

Abstract
Background: ST-segment elevation myocardial infarction (STEMI) is the most dramatic manifestation of coronary artery disease, acute STEMI is a clinical syndrome defined by characteristic symptoms of myocardial ischemia in association with persistent electrocardiographic ST elevation and subsequent release of biomarkers of myocardial necrosis. Reperfusion with thrombolysis or PCI (percutaneous coronary intervention) is the current standard of care for STEMI.

Aims and Objectives: The aim of the study was to compare the effectiveness of fibrinolytic therapy and primary PCI which are the available reperfusion strategies for STEMI.

Materials and Methods: This prospective and observational study was conducted at a tertiary care hospital in Bangalore. Patients presenting with STEMI to emergency department were treated with either fibrinolysis or PCI as per protocol. Patients in each arm were followed up to know the differences in outcome at discharge and 30-day follow-up.

Results: Patients admitted with STEMI had overall in hospital mortality of 17 (7.1%) patients, of which 9 (7.6%) patients were from fibrinolysis group and 8 (6.6%) patients from PCI group with no statistically significant difference (P = 0.760). There was significant incidence (P = 0.001) of reinfarct in fibrinolysis group (9.3%) when compared to PCI group (0%).

Conclusion: There was no statistically significant mortality difference at discharge and at 30 day between fibrinolysis and primary PCI in patients with STEMI in our study, this may be attributed to use of rescue PCI in failed fibrinolysis patients and early tricuspid valve repair in many patients after fibrinolysis.

Key words: Fibrinolysis; Primary PCI; ST-Segment Elevation; Myocardial Infarction

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Anupama M Articles by Sharath Kumar JV Articles by Shetty GG
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

M A, Jv SK, Gg S. A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2022; 12(11): 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

Web Style

M A, Jv SK, Gg S. A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. https://www.njppp.com/?mno=118248 [Access: November 01, 2025]. doi:10.5455/njppp.2023.13.09472202202102022

AMA (American Medical Association) Style

M A, Jv SK, Gg S. A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2022; 12(11): 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

Vancouver/ICMJE Style

M A, Jv SK, Gg S. A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2022), [cited November 01, 2025]; 12(11): 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

Harvard Style

M, A., Jv, . S. K. & Gg, . S. (2022) A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. Natl J Physiol Pharm Pharmacol, 12 (11), 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

Turabian Style

M, Anupama, Sharath Kumar Jv, and Shetty Gg. 2022. A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 12 (11), 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

Chicago Style

M, Anupama, Sharath Kumar Jv, and Shetty Gg. "A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

MLA (The Modern Language Association) Style

M, Anupama, Sharath Kumar Jv, and Shetty Gg. "A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 12.11 (2022), 1848-1853. Print. doi:10.5455/njppp.2023.13.09472202202102022

APA (American Psychological Association) Style

M, A., Jv, . S. K. & Gg, . S. (2022) A study to compare fibrinolytic therapy versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 12 (11), 1848-1853. doi:10.5455/njppp.2023.13.09472202202102022

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article